 Kindred Biosciences NASDAQ:KIN was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Thursday, Zacks.com reports. The firm presently has a 4.25 target price on the biopharmaceutical companys stock. Zacks Investment Researchs price objective indicates a potential upside of 14.56 from the stocks previous close. ... 